Literature DB >> 25152139

[Guideline for the diagnosis and management in the disease monitoring of patients with Chronic Myeloid Leukemia in China (2014)].

Xiaojun Huang.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25152139     DOI： 10.3760/cma.j.issn.0253-2727.2014.08.030

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN： 0253-2727


× No keyword cloud information.
  7 in total

1.  [Comparison of nilotinib vs imatinib as frontline therapy in newly diagnosed patients with chronic myeloid leukemia in chronic phase].

Authors:  L Yu; Y Z Qin; Y Y Lai; H X Shi; X J Huang; Y Hou; Q Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-12-14

2.  [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].

Authors:  X L Dou; L Yu; Y Z Qin; H X Shi; Y Y Lai; Y Hou; X J Huang; Q Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-11-14

3.  [Clinical significance of cytogenetic monitoring in chronic myeloid leukemia].

Authors:  C Y Pan; N Xu; B L He; R Cao; L B Liao; C X Yin; Y Q Lan; Z Y Lu; J X Huang; J Sun; R Feng; Q F Liu; X L Liu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-02-14

4.  [Dasatinib-related pulmonary adverse events in patients with chronic myeloid leukemia].

Authors:  S Yang; Y Z Qin; Y Y Lai; H X Shi; Y Hou; X J Huang; Q Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-12-14

5.  [The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-05-14

6.  [Clinical observation of chromosomal abnormalities in Ph negative cells of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors].

Authors:  J Wang; Yanli Zhang; J Zhou; Y L Zu; Z Li; Y P Song
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-05-14

7.  [Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].

Authors:  T Yuan; Y Y Lai; Y Z Qin; H X Shi; X J Huang; Y Hou; Q Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-02-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.